A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
Public ClinicalTrials.gov record NCT03938454. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Study identification
- NCT ID
- NCT03938454
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- Crizanlizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 100 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2019
- Primary completion
- Mar 27, 2023
- Completion
- Nov 28, 2023
- Last update posted
- Jan 12, 2026
2019 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Alabama | Birmingham | Alabama | 35294 | — |
| University of Connecticut Health Center | Farmington | Connecticut | 06030 | — |
| Childrens National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| Foundation for Sickle Cell Disease Research | Hollywood | Florida | 33021 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30303 | — |
| LSU Medical Center | Shreveport | Louisiana | 71130 | — |
| Childrens Hosp Boston Dept of Hematology | Boston | Massachusetts | 02115 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Brody School of Medicine | Greenville | North Carolina | 27834 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213-2548 | — |
| Prisma Health Upstate | Greenville | South Carolina | 29615 | — |
| University of Texas Medical School | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03938454, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03938454 live on ClinicalTrials.gov.